Generali Asset Management SPA SGR Makes New Investment in Insulet Co. (NASDAQ:PODD)

Generali Asset Management SPA SGR bought a new position in shares of Insulet Co. (NASDAQ:PODD - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 12,501 shares of the medical instruments supplier's stock, valued at approximately $3,264,000.

Other hedge funds also recently modified their holdings of the company. Integrated Wealth Concepts LLC boosted its holdings in shares of Insulet by 1.7% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 2,561 shares of the medical instruments supplier's stock valued at $596,000 after purchasing an additional 42 shares in the last quarter. Horizon Investments LLC lifted its position in shares of Insulet by 3.1% during the 4th quarter. Horizon Investments LLC now owns 1,387 shares of the medical instruments supplier's stock worth $362,000 after buying an additional 42 shares during the last quarter. Nisa Investment Advisors LLC boosted its stake in Insulet by 1.0% in the fourth quarter. Nisa Investment Advisors LLC now owns 4,388 shares of the medical instruments supplier's stock valued at $1,146,000 after buying an additional 43 shares in the last quarter. Glenmede Trust Co. NA raised its stake in Insulet by 2.3% during the third quarter. Glenmede Trust Co. NA now owns 2,080 shares of the medical instruments supplier's stock worth $484,000 after acquiring an additional 47 shares in the last quarter. Finally, Graypoint LLC raised its stake in Insulet by 5.3% during the fourth quarter. Graypoint LLC now owns 930 shares of the medical instruments supplier's stock worth $243,000 after acquiring an additional 47 shares in the last quarter.

Insiders Place Their Bets

In related news, EVP Eric Benjamin sold 12,394 shares of the business's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the transaction, the executive vice president now owns 11,383 shares in the company, valued at $3,187,240. The trade was a 52.13 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.47% of the company's stock.

Remove Ads

Analysts Set New Price Targets

PODD has been the topic of several research reports. TD Cowen lifted their price target on shares of Insulet from $264.00 to $324.00 and gave the company a "buy" rating in a report on Friday, January 3rd. JPMorgan Chase & Co. boosted their target price on shares of Insulet from $280.00 to $330.00 and gave the stock an "overweight" rating in a research note on Thursday, December 12th. Stifel Nicolaus increased their price target on Insulet from $245.00 to $293.00 and gave the company a "hold" rating in a research note on Friday, February 21st. Raymond James reissued an "outperform" rating and set a $328.00 price objective (up previously from $294.00) on shares of Insulet in a report on Friday, February 21st. Finally, Royal Bank of Canada began coverage on Insulet in a report on Thursday, March 6th. They issued an "outperform" rating and a $340.00 target price for the company. Four equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $292.06.

Insulet Trading Up 2.1 %

PODD stock traded up $5.72 during midday trading on Monday, hitting $274.04. The stock had a trading volume of 697,017 shares, compared to its average volume of 690,234. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The firm has a market cap of $19.24 billion, a P/E ratio of 47.33, a price-to-earnings-growth ratio of 3.62 and a beta of 1.29. The business has a fifty day moving average price of $272.04 and a two-hundred day moving average price of $257.37. Insulet Co. has a 1-year low of $160.19 and a 1-year high of $289.46.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.00 by $0.15. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The company had revenue of $597.50 million for the quarter, compared to the consensus estimate of $582.02 million. On average, sell-side analysts predict that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.